www.bjcancer.com British Journal of Cancer (BJC) is a well-established and respected international research journal, communicating high quality cancer research to a broadly based professional audience around the world.
The journal and its publisher, Nature Publishing Group, share a commitment to excellence in all aspects of editorial policy, publication and distribution.
Research papers are published under five headings: Clinical Studies, Translational Therapeutics, Molecular Diagnostics, Genetics and Genomics, and Epidemiology. BJC also publishes commissioned mini-reviews on current topics, some longer reviews, book reviews, editorials and correspondence.
BJC works with a distinguished team of international experts to ensure the highest standards of selection and review. All relevant papers are carefully considered, and once accepted, papers are published rapidly, with most appearing online within six weeks of acceptance.
Owned by Cancer Research UK, BJC reflects the aims of the charity - seeking understanding of the causes, prevention and treatment of cancer for the benefit of all, especially patients in the clinic. From its first issue, more than fifty years ago, the journal's mission has been to encourage communication of the very best cancer research from laboratories and clinics in all countries. This is shown today in its international authors, the breadth of its coverage, its consistent high standards and an editorial independence that has made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected in rising submissions and a rising impact factor, currently of 4.115, ranking 33/123 for Oncology.
BJC publishes 24 issues per year, which are available in print and online. Most papers also appear as advance online publications.
The Editor-in-Chief is Professor Adrian L Harris (University of Oxford).
